Drugs, Devices, and Diagnostics
Latest | Media coverage | Commentary | Academic Literature | Legislation | Reports and Government Documents
Covering prescription medicines and medical devices, which includes instruments, implants, scans and tests, as well as screening and health promoting interventions.
Latest
Media coverage
Most high-income countries ban direct advertising of prescription drugs – why does NZ still allow it?
New Zealand and the United States are the only high-income countries to allow unrestricted direct-to-consumer advertising of branded medicines, including the name of the drug and the condition for which it is prescribed.
Health New Zealand backtracks on Keytruda delay, will allow early access to some patients
Health New Zealand Te Whatu Ora has backed down on a plan to delay free access to a life-extending cancer drug after a backlash by patients and advocates.
Health NZ blocks free early access to cancer drug Keytruda
Patient advocates are accusing Health New Zealand of "cruelty" towards a small group of cancer patients, who are being forced to wait two more months for a newly-funded drug.
Commentary
NZ already spends less on health than Australia or Canada – we need proper funding, not ‘crisis’ management
We are being told the health system is in crisis, “on the brink of failure” – spending beyond its budget, waiting times getting longer, suffering from widespread staff shortages. Read...
How the Treaty really guides NZ’s drug-buying policies
Associate health minister David Seymour’s directive to Pharmac may streamline decisionmaking but it downplays the true role of the Treaty of Waitangi, writes Dominic O’Sullivan
Aotearoa New Zealand Rare Disorders Strategy
The Aotearoa New Zealand Rare Disorders Strategy sets out the direction for the health system to better support people and their whānau living with rare disorders.
Academic Literature
Impact of removing prescription co-payments on the use of costly health services: a pragmatic randomised controlled trial
Eliminating a small co-payment appears to have had a substantial effect on patients’ risk of being hospitalised.
How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe
Considering the recent advancements in economic evaluation methods, it is timely to rethink the role of the societal perspective in HTA guidelines and adopt a more comprehensive perspective to include all costs and consequences of healthcare services.
Is PHARMAC’s decision-making fair? Findings from an evaluation of decision-making in the New Zealand health system
The recent publication of the interim report of the PHARMAC Review Panel raises important questions of the role and processes of PHARMAC in securing equitable access to pharmaceuticals for all New Zealanders.
Legislation and Parliament
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
Reports and Government Documents
Cabinet material: Amendments to prescribing regulations for controlled drugs
Cabinet papers:
Amendments to prescribing regulations for controlled drugs
Misuse of Drugs Amendment Regulations
Statement of Intent
The Statement of Intent (SOI) is published every three years. This document provides an overview of our strategic priorities for the next four years, as well as specific performance targets and measures.
Key issues
HEALTH SERVICES AND SYSTEMS
EQUITY
DRUGS, DEVICE AND DIAGNOSTICS
PUBLIC HEALTH
DIGITAL HEALTH
TE TIRITI